Status:
COMPLETED
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Invasive Candidiasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast in...
Eligibility Criteria
Inclusion
- Clinical and Laboratory evidence of blood stream \&/or systemic candida infections
Exclusion
- Possible candida contamination
- Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections
- Acute or moderately severe liver disease
- Abnormal liver function tests
- Abnormal blood clotting for patients on blood thinners
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00250432
Start Date
January 1 2006
End Date
March 1 2008
Last Update
March 24 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.